We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+37.28%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$959M
AUM Growth
+$88.6M
Cap. Flow
-$54.3M
Cap. Flow %
-5.67%
Top 10 Hldgs %
33.04%
Holding
103
New
15
Increased
39
Reduced
35
Closed
12

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$17.6M
2
BSX icon
Boston Scientific
BSX
+$15.7M
3
KALV
KalVista Pharmaceuticals
KALV
+$14.6M
4
MCK icon
McKesson
MCK
+$7.81M
5
FOLD
Amicus Therapeutics
FOLD
+$7.68M

Top Sells

Rank Stock Value
1
VRNA
Verona Pharma
VRNA
+$18.7M
2
LLY icon
Eli Lilly
LLY
+$17.3M
3
THC icon
Tenet Healthcare
THC
+$16.8M
4
RVTY icon
Revvity
RVTY
+$15.2M
5
COO icon
Cooper Companies
COO
+$14.8M

Sector Composition

Rank Sector Weight
1 Healthcare 94.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRNA
101
DELISTED
Verona Pharma
VRNA
– –
-197,898
Closed -$18.7M
ATYR
102
aTyr Pharma
ATYR
$53M
– –
-150,000
Closed -$761K
PHLT
103
DELISTED
Performant Healthcare Inc
PHLT
– –
-1,214,272
Closed -$4.86M
1 2 3 4
5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Parkman Healthcare Partners held 103 positions worth $959M, up 10% from $870M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Parkman Healthcare Partners withdrew a net $54.3M in Q3 2025, closing 12 positions and reducing 35 holdings. Its most notable exit was Verona Pharma, an estimated $18.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 99% a quarter earlier.

Against the trend, Parkman Healthcare Partners opened a new position in Biogen worth $18.2M.

  • Parkman Healthcare Partners's largest Q3 2025 buy was Biogen: 130,165 shares worth $18.2M.
  • Parkman Healthcare Partners added most to Boston Scientific in Q3 2025, an estimated $15.7M increase.
  • Parkman Healthcare Partners's biggest Q3 2025 reduction was Eli Lilly, cutting an estimated $17.3M.
  • Parkman Healthcare Partners fully exited Verona Pharma in Q3 2025, selling an estimated $18.7M.
  • Parkman Healthcare Partners's ten largest holdings make up 33% of its $959M portfolio in Q3 2025.
  • Parkman Healthcare Partners opened 15 new positions and closed 12 in Q3 2025.
  • Parkman Healthcare Partners's portfolio value rose 10% quarter-over-quarter to $959M.

Based on Parkman Healthcare Partners's 13F filing for Q3 2025, filed 14 Nov 2025.